Evidence map›Paper›PMID 32760270›Full record

ArticleFrontiers in pharmacology2020

Mitochondrial Heme Synthesis Enzymes as Therapeutic Targets in Vascular Diseases.

Trupti Shetty, Timothy W Corson

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. More than a ring: the emerging role of heme in angiogenesis.Cell communication and signaling : CCS · 2026
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease.The Journal of pharmacology and experimental therapeutics · 2023
    Review
  7. Frontiers in microbiology · 2023
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Ferrochelatase regulates retinal neovascularization.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2020
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Trupti ShettyDepartment of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, United States.
Timothy W CorsonDepartment of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, United States.

Funding

Indiana Clinical and Translational Sciences InstituteUL1TR001108 · NCATS · INDIANA UNIVERSITY INDIANAPOLIS · PI DENNE, SCOTT C., SHEKHAR, ANANTHA · 2013 to 2017
$23.3M
Ferrochelatase as a mediator of ocular angiogenesisR01EY025641 · NEI · UNIVERSITY OF TORONTO · PI Timothy W Corson · 2016 to 2026
$3.5M
NCATS NIH HHS UL1 TR001108NEI NIH HHS R01 EY025641
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

age-related macular degenerationangiogenesisdiabetic retinopathyelectron transport chainendothelial nitric oxide synthaseferrochelataseheme synthesisneovascularization

Identifiers

PMID32760270
PMCPMC7373750

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.